4 days ago · Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14. Axsome focuses on CNS conditions including depression, Alzheimer's disease …

3 days ago · Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is …

5 days ago · Months after the FDA accepted Axsome Therapeutics’ resubmission of its new drug application (NDA) in September 2024, the agency has approved AXS-07, an oral, rapidly …

5 days ago · Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome Therapeutics' (AXSM.O), opens new tab migraine treatment, the company said on Thursday. …

4 days ago · Axsome Therapeutics, Inc. A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy …

4 days ago · Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by …

Find the latest Axsome Therapeutics, Inc. (AXSM) stock quote, history, news and other vital information to help you with your stock trading and investing.

3 days ago · Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by …

4 days ago · Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. …

Nov 27, 2024 · Axsome now plans to move “expeditiously” toward an FDA filing, but it will first request a pre-new drug application meeting with the agency, the executive added.